Online inquiry

IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ5678MR)

This product GTTS-WQ5678MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GPNMB gene. The antibody can be applied in Breast Cancer research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 1
Species	Homo sapiens
RefSeq	NM_001005340.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	10457
UniProt ID	Q14956

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5678MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ1672MR	IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, Pseudo-UTP, 30 nt-poly(A))	mRNA	ACZ885
GTTS-WQ7194MR	IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	FMC63 scFv-8A-F9Z CAR
GTTS-WQ6516MR	IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, Pseudo-UTP, 30 nt-poly(A))	mRNA	CX-191
GTTS-WQ14777MR	IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	SGN-40
GTTS-WQ10030MR	IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	L19-131 I
GTTS-WQ12459MR	IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	NKTR-214
GTTS-WQ713MR	IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	A-623
GTTS-WQ5769MR	IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	CetuxiMab-GEX

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST